home | publications


1. ERG Oncoprotein Portrait in Prostate Cancer: Translational Potential.
Rosen P, Sesterhenn IA, Brassell S, McLeod DG, Srivastava S, Dobi A.
Nature Reviews Urology, in press (2012)

2. ERG Protein Expression And Genomic Rearrangement Status In Primary And Metastatic Prostate Cancer - A Comparative Study Of Two Monoclonal Antibodies.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W,  Scheble V, Böhm D, Sotlar K, Fend F, Tan S-H, Dobi A, Wernert N, Perner S.
Prostate Cancer Prostatic Dis, [Epub ahead of print] 2012.

3. Oncogenic Activation Of ERG, A Predominant Mechanism In Prostate Cancer.
Sreenath T, Dobi A, Petrovics G, Srivastava S.
Journal of Carcinigenesis, 10:37 [Epub ahead of print] 2011.

4. Elevated Osteonectin/SPARC Expression in Primary Prostate Cancer Predicts Metastatic Progression.
DeRosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Siefert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.
Prostate Cancer Prostatic Dis, [Epub ahead of print] 2011.

5. Prostate Cancer In Men 70 Years Old Or Older, Indolent Or Aggressive: Clinicopathological Analysis And Outcomes.
Brassell SA, Rice KR, Parker PM, Chen Y, Farrell JS, Cullen J, McLeod DG.
J Urol, 185(1): 132-7, 2011.

6. ERG Transcription Factor As An Immunohistochemical Marker For Vascular Endothelial Tumors And Prostatic Carcinoma.
Miettinen M., Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn, IA
Am J of Sur Pathol, 35:432-441, 2011

7.ERG Oncogene Modulates Prostaglandin Signaling in Prostate Cancer Cells.
Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S..
Cancer Biol Ther, 11:410-417, 2011.

8. Prostate Cancer Gene Expression Signature Of Patients With High Body Mass Index.
Sharad S, Srivastava A, Ravulapalli S, Parker P, Chen Y, Li H, Petrovics G, Dobi A.
Prostate Cancer Prostatic Dis, 14:22-29, 2011.

9. Prostate Cancer in Men Less Than the Age of 50: A Comparison of Race and Outcomes.
Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, Brassell SA
Urology, 78(1):110-5, 2011.

10. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG
BJU Int, 108(3):378-85, 2011. .

11. New data, new paradigms for treating prostate cancer patients-VI: novel hormonal therapy approaches.
Dreicer R, Bajorin DF, McLeod DG, Petrylak DP, Moul JW
Urology, 78(5 Suppl):S494-8, 2011

12. Highlights From The Prostate Cancer Genome Report.
Tan SH, Petrovics G, Srivastava S..
Asian J Androl, 13(5):659-60, 2011.

13. Low risk prostate cancer in men ≥ 70 years old: To treat or not to treat.
Rice KR, Colombo ML, Wingate J, Chen Y, Cullen J, McLeod DG, Brassell SA.
Urol Oncol, [Epub ahead of print] 2011.

14. Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort.
Cullen J, Brassell SA, Chen Y, Porter C, L'esperance J, Brand T, McLeod DG
Prostate Cancer, 2011:234519. [Epub ahead of print] 2011.

15. Words of wisdom. Re: Antibody-based detection of ERG rearrangement-positive prostate cancer.
McLeod DG, Dobi A
Eur Urol, 60(5):1123, 2011.

16. Prostate cancer: diagnostic performance of the PCA3 urine test.
Lee GL, Dobi A, Srivastava S.
Nature Reviews Urology, 8(3):123-4, 2011.